A Double-Blind Randomized Controlled Trial of Olanzapine Plus Sertraline Vs Olanzapine Plus Placebo for Psychotic Depression

Total Page:16

File Type:pdf, Size:1020Kb

A Double-Blind Randomized Controlled Trial of Olanzapine Plus Sertraline Vs Olanzapine Plus Placebo for Psychotic Depression ORIGINAL ARTICLE A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression The Study of Pharmacotherapy of Psychotic Depression (STOP-PD) Barnett S. Meyers, MD; Alastair J. Flint, MD; Anthony J. Rothschild, MD; Benoit H. Mulsant, MD; Ellen M. Whyte, MD; Catherine Peasley-Miklus, PhD; Eros Papademetriou, MA; Andrew C. Leon, PhD; Moonseong Heo, PhD; for the STOP-PD Group Context: Evidence for the efficacy of combination phar- Results: Treatment with olanzapine/sertraline was as- macotherapy has been limited and without positive trials sociated with higher remission rates during the trial than in geriatric patients with major depression (MD) with psy- olanzapine/placebo (odds ratio [OR], 1.28; 95% confi- chotic features. dence interval [CI], 1.12-1.47; PϽ.001); 41.9% of sub- jects who underwent combination therapy were in re- Objectives: To compare remission rates of MD with psy- mission at their last assessment compared with 23.9% of ␹2 chotic features in those treated with a combination of subjects treated with monotherapy ( 1=9.53, P=.002). atypical antipsychotic medication plus a serotonin reup- Combination therapy was comparably superior in both take inhibitor with those treated with antipsychotic mono- younger (OR, 1.25; 95% CI, 1.05-1.50; P=.02) and older therapy; and to compare response by age. (OR, 1.34; 95% CI, 1.09-1.66; P=.01) adults. Overall, tol- erability was comparable across age groups. Both age Design: Twelve-week, double-blind, randomized, con- groups had significant increases in cholesterol and tri- trolled trial. glyceride concentrations, but statistically significant in- creases in glucose occurred only in younger adults. Setting: Clinical services of 4 academic sites. Younger adults gained significantly more weight than older subjects (mean [SD], 6.5 [6.6] kg vs 3.3 [4.9] kg, Patients: Two hundred fifty-nine subjects with MD with P=.001). psychotic features randomized by age (Ͻ60 or Ն60 years) (mean [standard deviation (SD)], 41.3 [10.8] years in 117 Conclusions: Combination pharmacotherapy is effica- younger adults vs 71.7 [7.8] years in 142 geriatric par- cious for the treatment of MD with psychotic features. ticipants). Future research must determine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 Intervention: Target doses of 15 to 20 mg of olanza- weeks. pine per day plus masked sertraline or placebo at 150 to 200 mg per day. Trial Registration: clinicaltrials.gov Identifier: NCT00056472 Main Outcome Measure: Remission rates of MD with psychotic features. Arch Gen Psychiatry. 2009;66(8):838-847 AJOR DEPRESSION (MD) residual disability, and greater mortality than with psychotic fea- MD without psychosis.2,4,5,8,9 tures is a severe but po- Expert guidelines10,11 recommend treat- tentially treatable dis- ment of MD with psychotic features with order.1 Epidemiological either electroconvulsive therapy (ECT) or studies2,3 and studies of large samples of psy- pharmacotherapy that combines an anti- M4,5 chiatric patients indicate that 15% to 20% depressant with an antipsychotic medica- of individuals with major depression have tion. The guidelines were based on stud- psychotic features. Higher prevalence rates ies demonstrating low response rates of approximating 45% have been reported MD with psychotic features to tricyclic an- Author Affiliations are listed at 12-16 the end of this article. among elderly inpatients with depres- tidepressant (TCA) monotherapy and 6,7 16 Group Information: The sion. Major depression with psychotic fea- results from both a small controlled trial STOP-PD group members are tures is associated with poorer short-term and pooled analyses17-20 favoring combi- listed on page 845. outcomes, a longer time to recovery, greater nation treatment or ECT. (REPRINTED) ARCH GEN PSYCHIATRY/ VOL 66 (NO. 8), AUG 2009 WWW.ARCHGENPSYCHIATRY.COM 838 ©2009 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 A recent meta-analysis demonstrating that combina- belief. The presence of at least 1 clearly defined delusion was tion therapy was superior to antipsychotic mono- required, with or without hallucinations, as studies of MD with therapy included the only 3 controlled trials available.21 psychotic features have generally considered delusional depression and MD with psychotic features to be synony- The limited evidence for the efficacy of combination treat- 35-37 ment for MD with psychotic features may contribute to mous. The presence of moderately severe to severe depres- 22 sion was assured by requiring scores of 21 or higher on the 17- the underrecognition of delusions in patients with MD item Hamilton Depression Scale (HAM-D),38 which was and the low use of antipsychotic medications to treat MD administered using the GRID-HAM-D method.39 23,24 with psychotic features in community settings. In con- This study focused on the treatment of MD with psychotic trast to trials in young adults,16 geriatric trials have not features rather than syndromes in which psychotic and depres- demonstrated greater efficacy for combined TCA/ sive symptoms accompany dementia. Therefore, patients with conventional antipsychotic therapy compared with TCA/ dementia or histories of impaired cognition prior to the cur- placebo for either acute25 or post-ECT continuation treat- rent depressive episode were excluded. Patients were ex- ment26 but did demonstrate poorer tolerability of cluded if they met criteria for another Axis I psychotic or mood combination therapy. disorder; current body dysmorphic disorder or obsessive- The present study investigated the efficacy of combi- compulsive disorder; or substance abuse during the preceding 3 months. Additional exclusion criteria were the presence of nation treatment in patients with systematically diag- an unstable medical condition that might interfere with comple- nosed MD with psychotic features across a broad spec- tion of the 12-week trial; a neurological disease that might affect trum of illness severity and compared the efficacy and neuromuscular functioning, such as Parkinson disease; and on- tolerability between persons aged 18 to 59 years and those going need for medications known to cause depression or psy- aged 60 years and older. We compared olanzapine (an chosis. Patients with known hyperlipidemia or diabetes melli- atypical antipsychotic medication reported to have acute tus, including insulin-dependent diabetes, were allowed to enroll antidepressant effects in placebo-controlled trials27,28) com- if their metabolic conditions were stable. Patients were ex- bined with placebo relative to olanzapine combined with cluded if immediate ECT was indicated because of their re- sertraline hydrochloride, a selective serotonin reuptake fusal to eat or drink or imminent risk for suicide. Patients who inhibitor antidepressant reported to be effective for MD demonstrated current suicidal ideation without immediate in- 29 tent and those who had made a suicide attempt during the cur- with psychotic features. The design encouraged aggres- rent episode were allowed to begin the study on an inpatient sive dosing of both medications during a 12-week trial basis. Screening also involved baseline laboratory assess- to maximize remission rates that could be compared with ments, including measurement of thyroid-stimulating hor- 14,17,18,30,31 the high remission rates associated with ECT. mone, folate, and B12 concentrations; an electrocardiogram; and The following hypotheses were tested: whether (1) com- a toxicology screen to detect undisclosed illicit drug use. Fi- bination therapy would be more effective than atypical nally, patients were excluded if they had received 15 mg or more antipsychotic monotherapy; (2) younger adults would of olanzapine per day for a minimum of 4 weeks during the achieve higher remission rates than older adults; and current episode or if they were benefiting from their current (3) younger adults would tolerate treatment better than psychotropic medications regimen. older adults. INTERVENTION METHODS Eligible subjects were randomized to sertraline plus olanza- pine or olanzapine plus placebo using computer-generated lists, PARTICIPANTS with investigators and raters blind to treatment assignments. Randomization was stratified by site and age, with a block size Patients aged 18 years or older who were admitted to the in- of 4. Subjects taking antidepressant or antipsychotic medica- patient or ambulatory services of the 4 participating academic tions at entry had these tapered prior to randomization, though sites between December 2002 and June 2007 were eligible for a washout period was not enforced because of the severity of recruitment. The institutional review boards of the participat- illness anticipated in study participants. Subjects began taking ing institutions and a data safety monitoring board at the Na- 5 mg of olanzapine per day and 50 mg of sertraline hydrochlo- tional Institute of Mental Health approved study consent forms ride or matching placebo per day, with dose increases permit- and monitored the study’s progress. Informed consent was ob- ted every 3 days as tolerated. Frail elderly subjects initially re- tained from all subjects, either directly or through locally ap- ceived 2.5 mg of olanzapine and 25 mg of sertraline or placebo proved surrogate consent procedures. Strategies to identify eli- (one-half of a 50-mg or placebo tablet). Olanzapine was ad- gible patients varied by institution and included review of new ministered openly, sertraline and placebo under double-blind admissions, advertisements, and direct referrals by commu- conditions. An attempt was made to reach minimum doses of nity psychiatrists. 10 mg of olanzapine per day and 100 mg of sertraline or pla- Potentially eligible consenting subjects were assessed with cebo per day before the end of week 1. Doses were increased the Structured Interview for Clinical Diagnosis32 to assure that to 15 mg of olanzapine per day and 150 mg of sertraline or pla- DSM-IV-TR1 criteria for unipolar MD with psychotic features cebo per day during week 2, with further increases allowed to were met.
Recommended publications
  • Paranoid – Suspicious; Argumentative; Paranoid; Continually on The
    Disorder Gathering 34, 36, 49 Answer Keys A N S W E R K E Y, Disorder Gathering 34 1. Avital Agoraphobia – 2. Ewelina Alcoholism – 3. Martyna Anorexia – 4. Clarissa Bipolar Personality Disorder –. 5. Lysette Bulimia – 6. Kev, Annabelle Co-Dependant Relationship – 7. Archer Cognitive Distortions / all-of-nothing thinking (Splitting) – 8. Josephine Cognitive Distortions / Mental Filter – 9. Mendel Cognitive Distortions / Disqualifying the Positive – 10. Melvira Cognitive Disorder / Labeling and Mislabeling – 11. Liat Cognitive Disorder / Personalization – 12. Noa Cognitive Disorder / Narcissistic Rage – 13. Regev Delusional Disorder – 14. Connor Dependant Relationship – 15. Moira Dissociative Amnesia / Psychogenic Amnesia – (*Jason Bourne character) 16. Eylam Dissociative Fugue / Psychogenic Fugue – 17. Amit Dissociative Identity Disorder / Multiple Personality Disorder – 18. Liam Echolalia – 19. Dax Factitous Disorder – 20. Lorna Neurotic Fear of the Future – 21. Ciaran Ganser Syndrome – 22. Jean-Pierre Korsakoff’s Syndrome – 23. Ivor Neurotic Paranoia – 24. Tucker Persecutory Delusions / Querulant Delusions – 25. Lewis Post-Traumatic Stress Disorder – 26. Abdul Proprioception – 27. Alisa Repressed Memories – 28. Kirk Schizophrenia – 29. Trevor Self-Victimization – 30. Jerome Shame-based Personality – 31. Aimee Stockholm Syndrome – 32. Delphine Taijin kyofusho (Japanese culture-specific syndrome) – 33. Lyndon Tourette’s Syndrome – 34. Adar Social phobias – A N S W E R K E Y, Disorder Gathering 36 Adjustment Disorder – BERKELEY Apotemnophilia
    [Show full text]
  • DCF Pamphlet 155-2: Appendix 3
    DCF Pamphlet 155-2: Appendix 3 Appendix 3: The table below shows the ICD9 codes that are acceptable in the Substance Abuse and Mental Health Information System (SAMHIS). This replaces all previous versions of allowable ICD9 codes used in the Substance Abuse and Mental Health Information System. The following are the codes and their meaning. STATUS: 0 = Inactive, code is not usable, 1 = Active, this will show in SAMHIS. PROGRAM CODE: N = Not Active, M = Mental Health Code, S = Substance Abuse Code B = Behavioral Health (can be used for either a mental health or substance abuse diagnosis) NOTE: Codes with ‘N’ (Not Active) in the Program Code are for historical purposes only. ICD9 PROGRAM Code STATUS DESCRIPTION CODE 095.7 0 SYPHILIS OF TENDON/BURSA N 196.8 0 MAL NEO LYMPH NODE-MULT N 259.9 0 ENDOCRINE DISORDER NOS N 269.0 0 DEFICIENCY OF VITAMIN K N 289.9 0 BLOOD DISEASE NOS N 290 0 Senile and presenile organic psychotic conditions N 290.0 0 SENILE DEMENTIA UNCOMP N 290.1 0 Presenile dementia N 290.10 0 PRESENILE DEMENTIA N 290.11 0 PRESENILE DELIRIUM N 290.12 0 PRESENILE DELUSION M 290.13 0 PRESENILE DEPRESSION M 290.2 0 Senile dementia with delusional or depressive feat M 290.20 0 SENILE DELUSION M 290.21 0 SENILE DEPRESSIVE M 290.3 0 SENILE DELIRIUM N 290.4 0 Arteriosclerotic dementia N 290.40 0 ARTERIOSCLER DEMENT NOS N 290.41 0 ARTERIOSCLER DELIRIUM N 290.42 0 ARTERIOSCLER DELUSION M 290.43 0 ARTERIOSCLER DEPRESSIVE M 290.8 0 SENILE PSYCHOSIS NEC N 290.9 0 SENILE PSYCHOT COND NOS N 291 1 Alcohol psychoses S 291.0 1 DELIRIUM TREMENS
    [Show full text]
  • The Effect of Delusion and Hallucination Types on Treatment
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2016;29:29-35 Research / Araştırma DOI: 10.5350/DAJPN2016290103 The Effect of Delusion and Esin Evren Kilicaslan1, Guler Acar2, Sevgin Eksioglu2, Sermin Kesebir3, Hallucination Types on Ertan Tezcan4 1Izmir Katip Celebi University, Ataturk Training and Treatment Response in Research Hospital, Department of Psychiatry, Izmir - Turkey 2Istanbul Erenkoy Mental Health Training and Research Schizophrenia and Hospital, Istanbul - Turkey 3Uskudar University, Istanbul Neuropsychiatry Hospital, Istanbul - Turkey Schizoaffective Disorder 4Istanbul Beykent University, Department of Psychology, Istanbul - Turkey ABSTRACT The effect of delusion and hallucination types on treatment response in schizophrenia and schizoaffective disorder Objective: While there are numerous studies investigating what kind of variables, including socio- demographic and cultural ones, affect the delusion types, not many studies can be found that investigate the impact of delusion types on treatment response. Our study aimed at researching the effect of delusion and hallucination types on treatment response in inpatients admitted with a diagnosis of schizophrenia or schizoaffective disorder. Method: The patient group included 116 consecutive inpatients diagnosed with schizophrenia and schizoaffective disorder according to DSM-IV-TR in a clinical interview. Delusions types were determined using the classification system developed by Gross and colleagues. The hallucinations were recorded as auditory, visual and auditory-visual. Response to treatment was assessed according to the difference in the Positive and Negative Syndrome Scale (PANSS) scores at admission and discharge and the duration of hospitalization. Results: Studying the effect of delusion types on response to treatment, it has been found that for patients with religious and grandiose delusions, statistically the duration of hospitalization is significantly longer than for other patients.
    [Show full text]
  • Psychotic Symptoms in Post Traumatic Stress Disorder: a Case Illustration and Literature Review
    CASE REPORT SA Psych Rev 2003;6: 21-24 Psychotic symptoms in post traumatic stress disorder: a case illustration and literature review Adekola O Alao, Laura Leso, Mantosh J Dewan, Erika B Johnson Department of Psychiatry, State University of New York, Syracuse, NY, USA ABSTRACT Posttraumatic stress disorder (PTSD) is a condition being increasingly recognized. The diagnosis is based on the re-experiencing of a traumatic event. There have been reports of the presence of psychotic symptoms in some cases of PTSD. This may represent in- creased severity or a different diagnostic clinical entity. It has also been suggested that psychotic symptoms may be over-represented in the Hispanic population. In this manuscript, we describe a case to illustrate this relationship and we review the current literature on the relationship of psychotic symptoms among PTSD patients. The implications regarding diagnosis, treatment, and prognosis are discussed. Keywords: Psychosis; PTSD; Trauma; Hallucinations; Delusions; Posttraumatic stress disorder. INTRODUCTION the best of our knowledge is the first report of psychotic symp- Posttraumatic stress disorder (PTSD) is a psychiatric illness for- toms in a non-veteran adult with PTSD. mally recognized with the publication of the third edition of the Diagnostic and Statistical Manual of the American Psychiatric CASE ILLUSTRATION Association in 1980.1 Re-experiencing of traumatic events as A 37 year-old gentleman was admitted to a state university hos- recurrent unpleasant images, nightmares, and intrusive feelings pital inpatient setting after alerting his wife of his suicidal is a core characteristic of PTSD.2 Most PTSD research has oc- thoughts and intent to slit his throat with a kitchen knife.
    [Show full text]
  • Quick Lesson About
    QUICK Delusional Disorder: Grandiose Type LESSON ABOUT Description/Etiology Delusional disorder is characterized by the presence for at least one month of delusions and the absence of other symptoms associated with psychotic, mood, or personality disorders that usually include delusions. Delusions are fixed beliefs that persist despite objective evidence that they are not true. Whether a particular belief is considered delusional varies from culture to culture; to be considered a delusion the belief cannot be accepted by members of the believer’s own culture or subculture. Delusions are categorized as either nonbizarre or bizarre. Nonbizarre delusions are beliefs that could conceivably be true (e.g., a life partner having an affair, being the object of unspoken love, being spied on by a government agency), whereas bizarre delusions have no possible basis in reality (e.g., having all of one’s organs replaced without surgery, being controlled by messages received from the CIA through a hat made of aluminum foil). The primary change in criteria for diagnosis of delusional disorder in the Diagnostic and Statistical Manual of Mental Health Disorders, fifth edition (DSM-5) from the fourth edition of the manual is the removal of the requirement that delusions are nonbizarre. The criteria for delusional disorder are delusions of at least one month’s duration; criterion A for schizophrenia has never been met (nonprominent hallucinations that are related to the theme of the delusion may be present); functioning is not noticeably impaired and behavior is not odd (except possibly for the direct impact and ramifications of the delusion); symptoms of mood disorders, if any, are brief relative to the duration of the delusion; and the delusion is not directly due to a general medical condition or the physiological effect of a substance.
    [Show full text]
  • Accurate Diagnosis of Primary Psychotic Disorders the Care Transitions Network
    Accurate Diagnosis of Primary Psychotic Disorders The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health Netsmart Technologies Objectives • By the completion of this webinar, participants should understand that the diagnoses of primary psychotic disorders will change early in the course of illness. • Participants will understand that when mood and psychotic symptoms overlap, diagnosis can further change over the patient’s lifetime. • Participants will be be able to use DSM-5 criteria to diagnose primary psychotic disorders and schizoaffective disorder. What diagnoses are on your differential? Think broadly. Differential should Include… • Schizophrenia • Schizophreniform Disorder • Brief Psychotic Disorder • Delusional Disorder • Other Specified Psychotic Disorder • Unspecified Psychotic Disorder Differential should exclude… Symptoms due to a medical condition or the effects of a medication or substance abuse Mood disorders with psychosis The timeline of psychotic symptoms is crucial for distinguishing between schizophrenia-spectrum disorders For psychotic disorders, the most accurate diagnosis can change as symptoms change over time Delusional Disorder Unspecified Psychotic Schizophreniform Schizophrenia Disorder Disorder Brief Psychotic Disorder JANUARY FEBRUARY MARCH APRIL MAY JUNE Symptoms resolve Brief Psychotic Disorder Symptoms Delusional Disorder resolve Schizophreniform Disorder Schizophrenia 6 month mark 1 month mark Also important for distinguishing schizophrenia-spectrum disorders are …..the psychotic symptom domains ….the frequency & severity of symptoms Schizophrenia Schizophrenia Negative Signs & Disorganized Signs 5 Symptoms Grossly Disorganized or Catatonic Behavior 4 Disorganized Speech 3 ≥ 2/5 key symptom domains Each present for a significant portion of time during a 1 month Positive Symptoms period. (Or less if successfully treated).
    [Show full text]
  • Sleep Disturbances in Patients with Persistent Delusions: Prevalence, Clinical Associations, and Therapeutic Strategies
    Review Sleep Disturbances in Patients with Persistent Delusions: Prevalence, Clinical Associations, and Therapeutic Strategies Alexandre González-Rodríguez 1 , Javier Labad 2 and Mary V. Seeman 3,* 1 Department of Mental Health, Parc Tauli University Hospital, Autonomous University of Barcelona (UAB), I3PT, Sabadell, 08280 Barcelona, Spain; [email protected] 2 Department of Psychiatry, Hospital of Mataró, Consorci Sanitari del Maresme, Institut d’Investigació i Innovació Parc Tauli (I3PT), CIBERSAM, Mataró, 08304 Barcelona, Spain; [email protected] 3 Department of Psychiatry, University of Toronto, #605 260 Heath St. West, Toronto, ON M5T 1R8, Canada * Correspondence: [email protected] Received: 1 September 2020; Accepted: 12 October 2020; Published: 16 October 2020 Abstract: Sleep disturbances accompany almost all mental illnesses, either because sound sleep and mental well-being share similar requisites, or because mental problems lead to sleep problems, or vice versa. The aim of this narrative review was to examine sleep in patients with delusions, particularly in those diagnosed with delusional disorder. We did this in sequence, first for psychiatric illness in general, then for psychotic illnesses where delusions are prevalent symptoms, and then for delusional disorder. The review also looked at the effect on sleep parameters of individual symptoms commonly seen in delusional disorder (paranoia, cognitive distortions, suicidal thoughts) and searched the evidence base for indications of antipsychotic drug effects on sleep. It subsequently evaluated the influence of sleep therapies on psychotic symptoms, particularly delusions. The review’s findings are clinically important. Delusional symptoms and sleep quality influence one another reciprocally. Effective treatment of sleep problems is of potential benefit to patients with persistent delusions, but may be difficult to implement in the absence of an established therapeutic relationship and an appropriate pharmacologic regimen.
    [Show full text]
  • Is Faith Delusion?
    Is Faith Delusion? Professor Andrew Sims It has been claimed that God is a delusion. I plan to examine that proposition from the standpoint of psychopathology. Delusion has now become a psychiatric word. Although in the past, the word delusion could refer to being fooled or cheated 1, in modern speech it always implies a suspicion of psychiatric illness. It has been appropriated by psychiatry and invariably implies a psychiatric diagnosis. If I am deluded, then I am necessarily mentally ill. In English law, delusion has been the cardinal feature of insanity for the last 200 years 2. It is a mitigating circumstance and can convey diminished responsibility. It is, therefore, within our professional competence as psychiatrists to say what is, and is not, delusion. I have had the temerity to entitle this, ‘Is faith delusion?’ as if I could answer that question for all faiths and, therefore, know about all religions and philosophies. Of course, this is not so, but there is a dilemma here; the person who can state, objectively, ‘religion is, or says…’ , in doing so, puts himself outside religion, and all religion, each faith, can only be truly known from inside. I therefore hope that the disadvantage of not being able to speak for all religions is outweighed by knowing well the subjective experience of one type of believer. Are all people with religious belief, a priori, suffering from mental illness? Sigmund Freud in 'Moses and Monotheism’ stated that belief in a single God is delusional 3. His contemporary, William James, was somewhat more circumspect and considered that spiritual and psychotic experiences were broadly distinguishable 4.
    [Show full text]
  • The ICD-10 Classification of Mental and Behavioural Disorders Diagnostic Criteria for Research
    The ICD-10 Classification of Mental and Behavioural Disorders Diagnostic criteria for research World Health Organization Geneva The World Health Organization is a specialized agency of the United Nations with primary responsibility for international health matters and public health. Through this organization, which was created in 1948, the health professions of some 180 countries exchange their knowledge and experience with the aim of making possible the attainment by all citizens of the world by the year 2000 of a level of health that will permit them to lead a socially and economically productive life. By means of direct technical cooperation with its Member States, and by stimulating such cooperation among them, WHO promotes the development of comprehensive health services, the prevention and control of diseases, the improvement of environmental conditions, the development of human resources for health, the coordination and development of biomedical and health services research, and the planning and implementation of health programmes. These broad fields of endeavour encompass a wide variety of activities, such as developing systems of primary health care that reach the whole population of Member countries; promoting the health of mothers and children; combating malnutrition; controlling malaria and other communicable diseases including tuberculosis and leprosy; coordinating the global strategy for the prevention and control of AIDS; having achieved the eradication of smallpox, promoting mass immunization against a number of other
    [Show full text]
  • Mood Disorders Agenda
    Mood Disorders Agenda • Statistics on MDD • Mood Disorders • Major Depressive Disorder • Bipolar • Schizophrenia • Other Mood Disorders Statistics The National Institute of Mental Health (NIMH) conservatively estimates the total costs associated with serious mental illness, those disorders that are severely debilitating and affect about 6 percent of the adult population, to be in excess of $300 billion per year. This estimate is based on 2002 data from the Substance Abuse and Mental Health Services Administration (SAMHSA) , the Social Security Administration , and findings from the NIMH-funded National Comorbidity Survey – Replication (NCS-R) The prevalence of a major mood disorder (Depression, BPD) in a given year in the Medicare population is only ~5% but the lifetime prevalence of a major mood disorder is ~20%.1 1According to the NIH the one year prevalence of a major depressive episode (not BPD) is anywhere from 5-16% depending on the patient’s age with younger patients having a higher prevalence in any given year. Since the diagnosis of “Major Depression in Remission” considers the lifetime prevalence the figure most likely exceeds 20% for all mood disorders combined. Major Depressive Disorder (MDD) According to the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) , five or more of the symptoms listed below must be present during the same 2-week time period that represents changes in functioning. At least one symptom is either a depressed mood or loss of interest. Depressed mood most of the day,
    [Show full text]
  • Psychosis in Children and Adolescents
    PSYCH TLC DEPARTMENT OF PSYCHIATRY DIVISION OF CHILD & ADOLESCENT PSYCHIATRY UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES PSYCHIATRIC RESEARCH INSTITUTE Psychosis in Children and Adolescents Written by: Jody L. Brown, M.D. Assistant Professor D. Alan Bagley, M.D. Chief Resident Department of Psychiatry Division of Child & Adolescent Psychiatry University of Arkansas for Medical Sciences Initial Review by: Laurence Miller, M.D. Clinical Professor, Medical Director, Division of Behavioral Health Services Arkansas Department of Human Services Initially Developed: 1-31-2012 Updated 3-31-2014 by: Angela Shy, MD Assistant Professor Department of Psychiatry Division of Child & Adolescent Psychiatry University of Arkansas for Medical Sciences Work submitted by Contract # 4600016732 from the Division of Medical Services, Arkansas Department of Human Services 1 | P a g e Department of Human Services Psych TLC Phone Numbers: 501-526-7425 or 1-866-273-3835 The free Child Psychiatry Telemedicine, Liaison & Consult (Psych TLC) service is available for: Consultation on psychiatric medication related issues including: . Advice on initial management for your patient . Titration of psychiatric medications . Side effects of psychiatric medications . Combination of psychiatric medications with other medications Consultation regarding children with mental health related issues Psychiatric evaluations in special cases via tele-video Educational opportunities This service is free to all Arkansas physicians caring for children. Telephone consults are made within 15 minutes of placing the call and can be accomplished while the child and/or parent are still in the office. Arkansas Division of Behavioral Health Services (DBHS): (501) 686-9465 http://humanservices.arkansas.gov/dbhs/Pages/default.aspx 2 | P a g e Table of Contents 1.
    [Show full text]
  • De-Rationalising Delusions
    De-Rationalising Delusions Authors: Vaughan Bell,1,2 Nichola Raihani,3 Sam Wilkinson4 1. Research Department of Clinical, Educational and Health Psychology, University College London 2. Psychological Interventions Clinic for outpatients with Psychosis (PICuP), South London and Maudsley NHS Foundation Trust 3. Department of Experimental Psychology, University College London 4. Department of Sociology, Philosophy and Anthropology, Exeter University 1 Abstract Due to the traditional conceptualisation of delusion as ‘irrational belief’, cognitive models of delusions largely focus on impairments to domain-general reasoning. Nevertheless, current rationality-impairment models do not account for the fact that i) equivalently irrational beliefs can be induced through adaptive social cognitive processes, reflecting social integration rather than impairment; ii) delusions are overwhelmingly socially-themed; iii) delusions show a reduced sensitivity to social context, both in terms of how they are shaped and how they are communicated. Consequently, we argue that models of delusions need to include alteration to coalitional cognition – processes involved in affiliation, group perception, and the strategic management of relationships. This approach has the advantage of better accounting for both content (social themes) and form (fixity) of delusion. It is also supported by the established role of mesolimbic dopamine in both delusions and social organisation, and the ongoing reconceptualisation of belief as serving a social organisational function.
    [Show full text]